Macclesfield, United Kingdom

Abid Suleman

USPTO Granted Patents = 1 

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2011

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Abid Suleman: Advancements in Chemical Compounds for Diabetes Treatment

Introduction

Abid Suleman, located in Macclesfield, GB, is a notable inventor recognized for his contributions in the field of chemical compounds. With a focus on medical advancements, he has developed innovative solutions aimed at combating serious health issues, particularly type 2 diabetes.

Latest Patents

Suleman's most recent patent revolves around a novel group of chemical compounds defined by Formula (I) or its salts. This invention is specifically aimed at the treatment or prevention of diseases mediated through glucokinase (GLK), such as type 2 diabetes. The patent details not only the chemical compositions but also the potential pharmaceutical applications and methods for preparing these compounds.

Career Highlights

Abid Suleman works at AstraZeneca, a leading global biopharmaceutical company that emphasizes innovation in improving patient outcomes. His role at AstraZeneca has allowed him to contribute significantly to research and development processes, showcasing his dedication to solving complex health challenges.

Collaborations

Throughout his career, Suleman has collaborated with talented colleagues such as Leonie Campbell and Kurt G Pike. These partnerships reflect a commitment to teamwork in the pursuit of impactful innovations in the pharmaceutical sector.

Conclusion

Abid Suleman's work exemplifies the critical intersection of innovation and healthcare. With his patented chemical compounds, he is contributing to the ongoing fight against diabetes, showcasing the vital role of inventors in developing solutions that can change lives. His affiliation with AstraZeneca further underscores the importance of collaboration in advancing medical treatments.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…